Icli F, Ezdinli E Z, Costello W, Berard C W, Bennett J M, Carbone P P
Cancer. 1978 Oct;42(4):1936-42. doi: 10.1002/1097-0142(197810)42:4<1936::aid-cncr2820420436>3.0.co;2-g.
34 patients with the diagnosis of diffuse well-differentiated lymphocytic lymphoma (DLWD), confirmed by a Pathology Panel, who were entered on a previously reported Eastern Cooperative Oncology Group study (EST 1472), were analyzed for response and survival. The response rates were as follows: CR 32%, PR 39%, NC or PD 29%. Survival analysis according to chemotherapy response revealed an estimated two-year survivorship of CR 89%, PR 65%, NC 69%, and PD 44%. Comparison with NLPD entered on the same study showed a two-year survival of 83% for NLPD and 67% for DLWD, indicating significantly poorer survival for DLWD as compared to NLPD (p less than .05). Median survival for DLWD from diagnosis was 39.0 + months. The presence of lymphocytosis over 4000/mm3 had little effect on response rates or survival. We conclude that DLWD is a less favorable lymphoma type than NLPD and should be treated with aggressive chemotherapy since achievement of CR seems to effect survival favorably.
34例经病理小组确诊为弥漫性高分化淋巴细胞淋巴瘤（DLWD）的患者，参加了先前报道的东部肿瘤协作组研究（EST 1472），对其反应和生存情况进行了分析。反应率如下：完全缓解（CR）32%，部分缓解（PR）39%，疾病稳定或进展（NC或PD）29%。根据化疗反应进行的生存分析显示，估计两年生存率为：CR 89%，PR 65%，NC 69%，PD 44%。与参加同一研究的非高分化淋巴细胞淋巴瘤（NLPD）相比，NLPD的两年生存率为83%，DLWD为67%，表明DLWD的生存率明显低于NLPD（p<0.05）。DLWD从诊断开始的中位生存期为39.0+个月。淋巴细胞计数超过4000/mm3对反应率或生存率影响不大。我们得出结论，DLWD是一种比NLPD预后更差的淋巴瘤类型，应采用积极的化疗进行治疗，因为达到CR似乎对生存有良好影响。
